Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT03064854
- Locations
- 🇺🇸
UCLA Santa Monica Hematology / Oncology SC-2, Santa Monica, California, United States
🇺🇸Henry Ford Health System SC, Detroit, Michigan, United States
🇺🇸Stanford Cancer Center SC, Stanford, California, United States
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
- Conditions
- Advanced Nsclc
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 232
- Registration Number
- NCT03062800
- Locations
- 🇨🇳
Qilu hospital of Shandong University, Jinan, Shandong, China
Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC
- Conditions
- Stomach NeoplasmsChemotherapy EffectChemotherapeutic Toxicity
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 240
- Registration Number
- NCT03061058
- Locations
- 🇨🇳
Ma'anshan People's Hospital, Ma'anshan, Anhui, China
🇨🇳Xuzhou Central Hospital, Xuzhou, Jiangsu, China
🇨🇳Suqian People's Hospital, Suqian, Jiangsu, China
A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT03061630
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients
- Conditions
- Stage IIIA Non-small Cell Lung Cancer
- Interventions
- Drug: PembrolizumabProcedure: Curative resectionProcedure: Neoadjuvant concurrent chemoradiotherapyDrug: CisplatinDrug: Paclitaxel
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT03053856
- Locations
- 🇰🇷
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 96
- Registration Number
- NCT03050437
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
- Conditions
- Biliary Tract Neoplasms
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT03046862
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 164
- Registration Number
- NCT03047265
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
- Conditions
- Small Cell Lung Carcinoma Extensive Disease
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 987
- Registration Number
- NCT03043872
- Locations
- 🇺🇦
Research Site, Zaporizhzhia, Ukraine
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
- Conditions
- Head and Neck Neoplasms
- Interventions
- Biological: PembrolizumabDrug: PlaceboDrug: CisplatinRadiation: Accelerated Fractionation (AFX) RadiotherapyRadiation: Standard Fractionation (SFX) Radiotherapy
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 804
- Registration Number
- NCT03040999
- Locations
- 🇺🇸
UCLA Medical Center ( Site 0273), Los Angeles, California, United States
🇵🇱Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1007), Gdynia, Poland
🇵🇱Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie ( Site 1000), Warszawa, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.